LUCENTIS

Formula & Concentration

LUCENTIS – ranibizumab 0.3 mg/0.05 mL and 0.5 mg/0.05 mL intravitreal syringe

Manufacturer

Genentech Inc

Indications

diabetic macular edema; choroidal neovascularization; neovascular age-related macular degeneration; central retinal vein occlusion with macular edema; diabetic retinopathy; branch retinal vein occlusion with macular edema

Product Options

Package Size

NDC #

Presentation

0.3 MG/0.05

50242-0082-03

VIAL

0.5 MG/0.05

50242-0080-03

SOLUTION

Shelf Life and Storage

Fridge (2-8°C)